Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
The CAP transfusion medicine accreditation checklist has been revised to enhance patient, donor, and blood bank safety.
Point-of-care (POC) testing for sexually transmitted infections (STIs) is crucial for combating the rising STI rates, particularly among marginalized groups.
A new general susceptibility subsection in the microbiology checklist consolidates requirements for antibacterials, antifungals, and antimycobacterials, aiming for clarity and a broader focus beyond bacteriology.
SPONSORED ROUNDTABLES
Thermo Fisher Scientific’s SwiftArrayStudio microarray analyzer was developed in response to customer needs for simpler workflows, more consistent turnaround times, and lower operational burden in genomics labs.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Billing
Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
March 2014—Quest Diagnostics will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis, and treatment for four strains of viral hepatitis in the U.S. Under terms of the multiyear contract, Quest will provide CDC researchers with analytics expertise and access to the company’s national Health Trends database of de-identified clinical testing hepatitis data.